-
Feb 16, 2024 Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
-
Nov 21, 2023 Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States
-
Sep 5, 2023 Apotex Corp. Launches Brimonidine Tartrate Ophthalmic Solution, 0.1% in the United States
-
Aug 26, 2023 Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States
-
Apr 19, 2023 Apotex Receives FDA’s Drug Shortage Assistance Award
-
Apr 3, 2023 SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals
-
Sep 28, 2022 SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals
-
Jul 20, 2022 First Generic Alternative to Eliquis® Now Available in Canada
-
May 17, 2022 Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis
-
Apr 12, 2022 Apotex Corp. Launches Generic of Abraxane® in the United States
-
Feb 2, 2021 Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings
-
May 26, 2020 APOTEX CORP. DONATES CRITICAL MEDICINES IN THE FIGHT AGAINST COVID-19
-
May 26, 2020 Canada’s largest pharmaceutical manufacturer donates thousands of bottles of hand sanitizer to hospitals across Quebec
-
May 25, 2020 Toronto Company Launches Hiring Blitz During COVID-19
-
Apr 21, 2020 Canada’s Apotex Donates Two Million Dosages of Hydroxychloroquine to the Public Health Agency of Canada
-
Apr 17, 2020 Canada’s Apotex Donates Critical N95 Masks to Support Frontline Healthcare Workers
-
Apr 13, 2020 Canada’s Largest Pharmaceutical Company Produces Hand Sanitizer to Support the Fight Against COVID-19
-
Mar 23, 2020 APOTEX DONATES HYDROXYCHLOROQUINE FOR A CLINICAL STUDY TO PREVENT INFECTION FROM COVID-19 WITH FRONT LINE HEALTH CARE WORKERS
-
Mar 5, 2020 Apotex Statement: Drug Supply and COVID-19
-
Sep 20, 2018 ACCC announces clearance of the merger of Arrow Pharmaceuticals & Apotex Australia & NZ merger
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.
-
May 25, 2025
Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.